Christopher W. Krueger - 03 Apr 2023 Form 4/A - Amendment Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Business Officer
Signature
/s/ Christopher Krueger
Issuer symbol
VTYX
Transactions as of
03 Apr 2023
Net transactions value
-$461,126
Form type
4/A - Amendment
Filing time
04 May 2023, 16:03:53 UTC
Date Of Original Report
05 Apr 2023
Previous filing
18 Jan 2023
Next filing
04 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Options Exercise $28,221 +7,972 +2.8% $3.54 290,642 03 Apr 2023 Direct F1
transaction VTYX Common Stock Options Exercise $3,819 +475 +0.16% $8.04 291,117 03 Apr 2023 Direct F1
transaction VTYX Common Stock Sale $493,166 -15,000 -5.2% $32.88 276,117 03 Apr 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This amendment is being filed to correct the transaction date reported in the Form 4 filed April 5, 2023.
F2 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
F3 Represents the weighted average share price of an aggregate total of 15,000 shares sold in the price range of $32.5744 to $33.495. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.